|Videos|October 14, 2022

Dr. Parker on next steps with mpMRI in prostate cancer

Author(s)Urology Times staff

William P. Parker, MD, shares his expectations for the future of multiparametric MRI (mpMRI) in prostate cancer and where micro-ultrasound may fit alongside mpMRI in the paradigm. Parker is a practicing urologist at The University of Kanas Health System and an assistant professor at the University of Kansas Medical Center.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Published data support PSMA-PET–guided selection for 177Lu-rosopatamab tetraxetan in mCRPC

ByHannah Clarke

July 22nd 2026

FDA approves generic Ga-68 PSMA-11 radiodiagnostic for prostate cancer

ByHannah Clarke

June 10th 2026

PRIMARY2 trial supports PSMA PET-CT in equivocal prostate MRI work-up

ByDeclan Murphy, MB, BCH, BaO, FRACS, FRCS, Urol

March 23rd 2026

Laurence Klotz, MD, FRCSC, reveals the impact of micro-ultrasound on his prostate cancer practice

ByBenjamin P. Saylor, Strategic Content Lead,Hannah Clarke

March 18th 2026

EAU 2026: 64Cu-SAR-bisPSMA shows improved detection vs 68Ga-PSMA-11 in BCR of prostate cancer

ByHannah Clarke

March 17th 2026

Latest CME

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD

CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom

Kari Tikkinen, MD, PhD, discusses POISE-3 findings on tranexamic acid in urologic surgery

Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy

Mary Dunn, MSN, NP-C, OCN, RN, on advances reshaping advanced prostate cancer care